At a glance
ClinicalIndex Comparison RecordN/ACompleted· 282 enrolled
Drug / intervention
RENOVA iStim™ Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Study to Assess the Efficacy and Safety of the BlueWind RENOVA iStim™ System in the Treatment of Patients Diagnosed With Overactive Bladder (OASIS - OverActive Bladder StImulation System Study)
In Brief
A clinical study evaluating RENOVA iStim™ System for Treatment of Patients Suffering From Overactive Bladder (OAB). Completed, enrolled 282 participants across 23 sites in 4 countries.
Detailed Summary
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Netherlands, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartJun 2019
Primary CompletionOct 2022
Study CompletionJan 2025
TodayJul 2026
First PostedJul 24, 2018
Enrollment StartJun 12, 2019
Primary CompletionOct 28, 2022
Study CompletionJan 24, 2025
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.9 years ago
Interventions
RENOVA iStim™ Systemdevice
Tibial implantable neuromodulation device